Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mangafodipir CMR in HFpEF due to HCM or Cardiac Amyloidosis
2023-508118-40-01Phase 2Completed
- Sponsor
- IC Targets
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mangafodipir in heart failure with preserved ejection fraction (HFpEF), hypertrophic cardiomyopathy (HCM) and amyloid cardiomyopathy (2 arms), sponsored by IC Targets. Started Sep 2024; status: completed.
02
Drugs
mangafodipir
03
Conditions
heart failure with preserved ejection fraction (HFpEF)hypertrophic cardiomyopathy (HCM)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2023-508118-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508118-40-01.